Overview of Kalmivet

Property	Description
Active ingredient	Acepromazine maleate
Form	Tablet (Oral) and Liquid for Injection (Parenteral)
Pharmacological class	Phenothiazine derivative (Neuroleptic Agent)
Common use	Sedation and Tranquilization
Origin	Synthetic compound

What Type of Medicine is Kalmivet (Acepromazine)?

Kalmivet is a prescription-only veterinary medicinal product used to produce controlled sedation and tranquilization in animals, containing the synthetic compound Acepromazine maleate as its active ingredient. This compound is structurally a phenothiazine derivative, which is widely recognized as a neuroleptic agent. The classification of Acepromazine as a phenothiazine is important because this pharmacological class defines its specific mechanism group and distinguishes it from other general sedatives used in veterinary medicine for species such as dogs, cats, and horses. This substance is derived from the core phenothiazine molecule and is utilized for its central nervous system depressant effects.

Forms and Primary Purpose of Acepromazine

Acepromazine maleate is manufactured in two principal dosage forms: the oral solid preparation, typically a tablet, and a liquid for injection intended for parenteral use. The core function of Acepromazine is to manage anxiety, restlessness, and nervousness by providing deep, controllable tranquilization. This capability serves the general purpose of facilitating chemical restraint for handling during examinations or transport. Furthermore, its consistent calming effect makes it a valuable anesthetic adjunct or pre-anesthetic agent, preparing animals for surgery by smoothing the induction process and potentially reducing the total amount of general anesthetics required.

How Acepromazine Induces Tranquilization

Acepromazine works by inducing a generalized, predictable depressant effect on the central nervous system (CNS), which results in a state of calmness and muscular relaxation. This neurological effect is primarily achieved because the drug functions as a dopamine receptor antagonist, interfering with key brain signaling pathways that regulate motor activity and alertness. This high-level mechanism—modulating neurological function to reduce excitability—is the essential reason Acepromazine is employed, as it allows for the temporary and safe control of anxious or fractious target species.

Regulatory References

Acepromazine Maleate (veterinary drug label)

What side effects are possible with Kalmivet?

The official safety profile for Kalmivet (Acepromazine maleate) is primarily defined by its effects on the Cardiovascular and Nervous Systems, consistent with its classification as a phenothiazine derivative.

Adverse Reaction Scope

Category	Entity/Classification (Regulatory Basis)
Common/Expected Reactions	Hypotension (low blood pressure) and sedation are common, dose-related responses. Minor effects like transient protrusion of the third eyelid are also documented.
System-Organ Classes	Effects are concentrated in the Vascular, Cardiac, Nervous, and Hemic/Lymphatic systems, including transient decreases in red blood cell and platelet counts.
Serious Adverse Reactions	Regulatory documents list the potential for circulatory collapse (secondary to severe hypotension) and rare, idiosyncratic behavioral disorders such as aggression or nervousness. Paralysis of the retractor penis muscle is a serious adverse effect documented in horses.

Safety Constraints and Special Populations

Safety information specifies use constraints for specific clinical states and populations. The medicine is contraindicated in animals suffering from shock, hypovolemia, or severe depression. Caution is mandated for use in older or debilitated animals and those with hepatic dysfunction. Breed-specific sensitivity is noted, particularly for Boxer Dogs (increased cardiovascular risk) and some Collie breeds (MDR1 gene mutation), where effects may be intensified or prolonged. Exposure-related patterns note that severe hypotension can occur shortly after rapid administration, and effects may be prolonged in animals with liver disease.

Connection to the Overall Safety Profile

This structured safety information establishes that managing effects on the circulatory system is central to the drug's safety monitoring. The profile defines the boundaries of acceptable use by explicitly documenting serious risks and contraindications, reflecting how government regulatory sources organize the factual understanding of the medicine's risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Overdosage with Kalmivet (Acepromazine maleate) primarily manifests as Prolonged Central Nervous System (CNS) Depression, presenting as marked sedation, excessive lethargy, and sometimes motor restlessness or incoordination. Respiratory symptoms, such as bradypnea (slowed breathing), are documented presentations of severe over-administration. Regulatory labeling classifies overdosage as potentially life-threatening due to serious outcomes affecting the Cardiovascular system.

Overdose Classifications and Emergency Action

Life-threatening outcomes include acute dose-dependent hypotension leading to circulatory collapse and progression to convulsive seizures, unconsciousness, or death. Immediate veterinary attention or contacting emergency services is required upon suspicion of overdosage or the observation of these severe signs.

Official Overdose Management Statements

The procedural guidance mandates that Epinephrine is contraindicated for treating overdose-induced hypotension, as its use can cause further depression of blood pressure.
The treatment focuses on symptomatic and supportive care, utilizing other pressor amines (such as norepinephrine or phenylephrine) as the specific drugs of choice for managing acute circulatory compromise.
The need for continuous monitoring is implicit due to the risks of CNS and cardiovascular collapse.

Therapeutic Uses of Kalmivet

Main Uses and Benefits of Kalmivet (Acepromazine)

The primary therapeutic benefit of Kalmivet plays a role in managing certain distressing symptoms and acute behavioral challenges. The medication is applied in contexts marked by increased discomfort or tension and is commonly used across conditions presenting with acute episodes. It provides supportive relief for several indications, including the tranquilization of animals presenting with excessive excitement, restlessness, and nervousness, and may be part of symptomatic management as a pre-anesthetic agent before surgical procedures. It is also relevant for easing symptoms associated with motion sickness.

“The medication is applied in scenarios where additional management of symptoms related to high arousal is required for procedures.”

Tranquilization and Procedural Support

This domain is commonly used to help with symptom clusters that may become intense or disruptive, particularly during veterinary handling or grooming. The core benefit may assist with maintaining functional stability for veterinary care, helping patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Situational Distress

Kalmivet is generally considered relevant when short-term symptomatic assistance is needed for transport, examination, or minor procedures, and may support general well-being during symptomatic phases.

Regulatory References

U.S. Food and Drug Administration (FDA) approved label overview

Eligibility and Restrictions for Use

Kalmivet is officially approved for use in dogs, cats, and horses. However, eligibility for use is defined by a strict set of contraindications and cautions mandated by government regulatory agencies.

Absolute Contraindications (Prohibited Use)

Use is absolutely prohibited in certain animals based on their health status or intended use:

Food Animals: Must not be used in animals intended for human consumption (e.g., specific horse populations).
Physiological State: Contraindicated in animals with existing heart failure, hypovolemia, shock, or severe dehydration.
Neurological/Hematological: Prohibited in animals with epilepsy or a known tendency to convulsions, or those with haematological disorders (e.g., anemia or coagulopathies).
Toxicology: Must not be used to treat tremors associated with organic phosphate poisoning or in conjunction with organophosphorus vermifuges (e.g., certain flea collars) or procaine hydrochloride.

Restricted Use and Special Populations

Conditional use is required in specific populations where sensitivities or increased risks are officially documented:

Category	Eligibility Rule (Use with Caution/Restriction)
Age and Reproduction	Dogs less than 3 months of age are contraindicated. Use during pregnancy and lactation is not established and is generally not recommended. Use in breeding stallions is prohibited due to the risk of penile paralysis.
Organ Function	Caution is required for animals with a history of liver dysfunction or hepatic disease.
Breed Sensitivity	Brachycephalic breeds (e.g., Boxers) and dogs with the ABCB1-1Δ (MDR1) gene mutation require special caution due to increased sensitivity, as do large breeds of dogs and Sighthounds.
General Health	Animals exhibiting symptoms of stress or debilitation require use with greater care and caution.

This regulatory framework establishes non-eligibility for compromised animals and mandates conditional use for sensitive breeds or those with specific organ weaknesses.

What should I know about interactions with other medicines?

The official interaction profile for Acepromazine maleate is classified by both specific pharmacodynamic and pharmacokinetic interactions, as well as combinations that are formally prohibited, according to regulatory labeling.

Documented Contraindications and Prohibitions

Co-administration is strictly prohibited with certain substances. Epinephrine is contraindicated for use in treating hypotension induced by phenothiazine derivatives, as this combination may lead to further blood pressure depression. The use of this drug is also prohibited with Organophosphates, including certain ectoparasiticides, due to the potential for toxicity potentiation. Procaine Hydrochloride is additionally restricted for co-administration.

Pharmacodynamic Potentiation

Acepromazine demonstrates an additive action when administered with other CNS depressants, such as narcotics and general anesthetics. This potentiation may require adjustment of the co-administered agent’s dose. Caution is advised when combining with Hypotensive Agents and Local Anesthetics due to documented risks of potentiating blood pressure-lowering effects.

Pharmacokinetic and Timing Rules

Interactions can reduce the amount of drug absorbed. Antacids, Antidiarrheal products, and Sucralfate are shown to interfere with the absorption of oral Acepromazine, resulting in a reduced concentration in the bloodstream. To mitigate this effect, mandatory administration rules require separation: Acepromazine must be given 2 hours before antacids or antidiarrheal products, and Sucralfate 2 hours after Acepromazine.

Population Sensitivity

The risk of prolonged effects is officially noted in specific populations. Since the drug relies on liver detoxification for clearance, animals with liver dysfunction may experience heightened effects. Furthermore, dogs with the ABCB1 (MDR1) gene mutation exhibit enhanced sedative effects due to sensitivity related to drug disposition.

Mechanism of Action

How Kalmivet Works

Primary Target: GABA-A Receptor Antagonism

Kalmivet functions as a non-competitive antagonist, binding at a site distinct from the active binding site on the GABA-A receptor in the central nervous system. This molecular interaction results in a conformational change that restricts the activity of the receptor-ionophore complex.

Ionic Cascade and Hyperpolarization

The antagonism of the GABA-A receptor complex causes a marked increase in the flux of the chloride ion Cl^- across the postsynaptic neuronal membrane. This elevated Cl^- influx generates a negative shift in the membrane potential, resulting in hyperpolarization. This immediate mechanistic cascade reduces the frequency of action potential generation and lowers the overall cellular excitability within the nervous system.

Secondary Modulation

In addition to its primary activity, Kalmivet modulates the function of the serotonin 5- HT1 A receptor. This effect is achieved through allosteric modulation, which contributes to the compound's overall physiological impact on neurotransmitter systems.

Dosage and Administration Information

Administration Routes and Dosage Calculation

Acepromazine maleate (Kalmivet) is administered through specific routes based on the required clinical application. The medication is available in two distinct dosage forms: tablets for oral use and a solution for injection for parenteral routes, including intravenous (IV), intramuscular (IM), and subcutaneous (SC) administration. Dosing is determined based on the patient's body weight and species.

Official Dosing Patterns

The required dose must be individualized and calculated in mg/lb or mg/100 lb depending on the species. For example, the oral dosing range for dogs is specified as 0.25 to 1.0 mg per pound of body weight, whereas the parenteral dose for cats is 0.5 to 1.0 mg per pound. A key principle for use is that the dose requirement in mg/lb generally decreases as the animal's weight increases, which guides appropriate dosage selection.

Timing and Procedural Conditions

The use pattern for this medication is restricted to short-term, intermittent administration, typically as a single dose for procedural support, and it is not intended for chronic, long-term use. Timing in relation to the intended effect is crucial: the oral tablet is given 45 to 60 minutes before the event. For the intravenous route, the dose is administered slowly, and a period of 15 minutes is allowed post-injection for the full effect to be achieved. Additionally, the tablets may be administered with or without food, and smaller doses are used with greater care when administering to debilitated or stressed patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kalmivet

I. Research Evidence for Tranquilization and Procedural Support

The core research exploring measured outcomes related to procedural support consists of comparative studies and clinical trials, primarily involving healthy adult dogs and horses. Research was applied in studies examining how patient compliance and cooperation levels change when the medicine is used prior to handling or transport. Studies monitored outcomes related to physical discomfort and levels of muscular relaxation. Findings describe patterns observed in the studies, which often focused on the measured onset and duration of the observed changes following administration.

II. Research Evidence as a Pre-anesthetic Agent

Research explored measured outcomes related to the compound when used before general anesthesia. This research base consists primarily of Randomized Controlled Trials (RCTs) and prospective clinical studies that compared its use in combination protocols against other pre-anesthetic regimens. Multiple trials reported patterns related to the measured dose requirement for the anesthetic induction agent when Kalmivet was included in the premedication protocol. Studies monitored systemic or functional imbalance, specifically detailing the measured cardiovascular variables throughout the early stages of anesthesia.

III. Research Evidence for Other Studied Applications

Kalmivet was studied for use in acute settings involving the prevention of nausea and vomiting associated with certain types of pain relief medication. Research utilized Randomized Prospective Clinical Studies to monitor the incidence of vomiting and nausea following the co-administration of the medications. Findings were mixed regarding the influence of dose on the observed outcome. The compound was also evaluated in research exploring its use as one component of a multi-drug combination protocol administered before stressful events.

VI. Areas of Uncertainty and Research Gaps

The research base includes several documented limitations where further study is needed. Comparative evidence is lacking against many newer tranquilizing agents now available, and the evidence quality varies across studies depending on the specific application. For its studied use in situational distress protocols, the evidence is focused on combination therapy, meaning that subgroup findings are uncertain regarding the independent role of Kalmivet.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Kalmivet (FAQ)

Q: Do I need a prescription from a doctor to get Kalmivet?

A: Yes, Kalmivet is classified as a prescription-only veterinary medicinal product. Official regulatory documents state that federal law restricts this drug to use by, or on the order of, a licensed veterinarian.

Q: Is Kalmivet considered a controlled substance?

A: Kalmivet is officially regulated as a prescription animal drug and is restricted for use by veterinarians. It is not listed as a DEA Schedule controlled substance in official US regulatory labeling.

Q: Why is Kalmivet not recommended for people with a history of certain conditions?

A: Kalmivet is a prescription-only veterinary medicinal product that is explicitly restricted for use in animals like dogs, cats, and horses. It is not approved, recommended, or authorized for use by humans.

Q: How is Kalmivet different from a vitamin or supplement?

A: Kalmivet is a prescription-only, synthetic pharmaceutical classified as a phenothiazine derivative and a neuroleptic agent, meaning it affects the nervous system. This classification means it is legally and chemically distinct from a vitamin or a dietary supplement, which are not regulated as prescription drugs.

Q: Is there a generic version of Kalmivet available?

A: Yes, the active ingredient in Kalmivet is Acepromazine maleate. Official FDA records confirm that approved generic versions of the drug are commercially available under its generic name.

Q: How quickly can I expect Kalmivet to start working?

A: Official information indicates that the oral tablet form is described as reaching its effect in approximately 45 to 60 minutes after administration. The duration of the tranquilizing effect is typically noted as lasting between 4 and 8 hours, though this can vary depending on the patient and the dose used.

Q: How long does the effect of one dose of Kalmivet typically last?

A: The tranquilizing effect is generally described in official literature as lasting 4 to 8 hours. Official information also notes that the overall duration can be highly variable depending on the individual, the species, and the specific dose administered.

Q: Is it possible to take Kalmivet with an anti-anxiety medicine?

A: Official labeling advises caution when using Kalmivet alongside other medications that depress the central nervous system (CNS), such as general anesthetics. Combining CNS depressants may result in an additive effect, which is noted in official documents as potentially requiring a dose change by the prescribing veterinarian.

Q: Does Kalmivet affect your ability to drive or operate machinery?

A: Kalmivet is a veterinary-only product and is not authorized for human use. For its approved use in animals, official labeling notes that the drug produces expected effects of sedation and central nervous system depression, which are incompatible with operating vehicles or machinery in humans.

Q: Is it normal to feel a bit tired when you first start Kalmivet?

A: Kalmivet is a veterinary medicinal product and is not intended for human use. For its approved use in animals, sedation and depression of the central nervous system are listed in official documents as common and expected dose-related responses.

Q: What kind of difference is there between Kalmivet and other similar drugs people take?

A: Kalmivet (Acepromazine maleate) is a prescription-only veterinary medicinal product that belongs to the pharmacological class of phenothiazine derivatives, also known as neuroleptic agents. This classification defines its core mechanism group and distinguishes it structurally and chemically from many other types of non-prescription or non-neuroleptic tranquilizers or sedatives.

Q: Is Kalmivet safe to take with alcohol, or should I avoid it?

A: Kalmivet is a veterinary medicinal product and is not authorized for human use. Regulatory documents warn that any substance with central nervous system (CNS) depressant activity, which includes alcohol, may have additive or potentiating effects when co-administered.

Q: What happens if I miss a day of taking Kalmivet?

A: Since Kalmivet is approved for short-term, intermittent use, a missed dose is not typically a concern. If the drug is intended for repeated use, official guidance suggests not doubling the dose and directing any questions about a missed dose to the prescribing veterinarian.

Q: Does Kalmivet cause weight gain or weight loss?

A: Weight gain or weight loss are not listed among the commonly reported or serious adverse reactions documented in the official regulatory safety profile for Kalmivet.

Q: Are there any routine lab tests needed while taking Kalmivet?

A: Official safety information notes that the drug relies on the liver for clearance and affects the blood system. While no routine tests are universally mandated in the general labeling, the need for baseline or follow-up bloodwork is determined by the prescribing veterinarian on a case-by-case basis.

Q: How long do doctors usually recommend staying on Kalmivet?

A: Official authorization for Kalmivet specifies its use for short-term, intermittent administration, often as a single dose for procedural support. It is not approved or recommended in regulatory documentation for chronic, long-term daily use.

Q: Is there a risk of dependency or addiction with Kalmivet?

A: Kalmivet is not classified as a controlled substance by the DEA. Due to its approved short-term, intermittent use, the official regulatory documentation does not contain warnings regarding risks of dependency or addiction.

Q: Does Kalmivet have any known long-term effects on the body?

A: Official documentation explicitly authorizes Kalmivet only for short-term, intermittent administration. As such, regulatory information does not contain data on the known long-term effects of chronic, daily use, as such use is not recommended.

Q: What should I do if I think I am having a side effect from Kalmivet?

A: Kalmivet is a veterinary medicinal product and is not approved for human consumption. Official guidance indicates that in the event an individual believes they have ingested the drug or are experiencing an adverse effect, contacting a Poison Control Center or emergency services is appropriate.

Q: Is it safe to suddenly stop taking Kalmivet?

A: Given that Kalmivet is approved only for short-term, intermittent use, the official information does not describe specific withdrawal syndromes associated with suddenly stopping chronic use. Information about stopping any medication is appropriately addressed by the prescribing veterinarian.

Q: Does Kalmivet affect sleep patterns?

A: Kalmivet is classified as a neuroleptic agent that acts as a central nervous system (CNS) depressant. This primary action causes sedation, which is an intended effect that influences the state of rest and wakefulness.

Q: Does Kalmivet interact with common pain relievers like ibuprofen?

A: Official labeling specifically warns against co-administration with other Central Nervous System (CNS) depressants due to potential additive effects. It is important that all products, including common pain relievers, be discussed with the prescribing veterinarian.

How should Kalmivet be stored and disposed of?

Kalmivet (acepromazine maleate) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure public safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at controlled room temperature (20 C to 25 C). Do not store above 25 C.
Protection	Protect from light and frost (do not freeze). Keep in a tightly closed, light-resistant container.
Shelf-Life	Do not use after the expiry date. Some injectable products must be discarded within 56 to 90 days after first opening.
Safety	Keep out of the sight and reach of children and securely out of reach of all animals to prevent accidental ingestion.

Disposal Instructions

Unused or expired Kalmivet must be handled as pharmaceutical waste. Disposal must be carried out in accordance with local and national regulations through an approved waste disposal plant or licensed site. The product must not be flushed into surface water or the sanitary sewer system due to environmental restrictions.

Kalmivet